Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating
Sage To Resume Full Ownership Of SAGE-324 Program As Biogen Terminates Collaboration Deal
Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug
Biogen to End Sage Deal for Neuro Candidate
Express News | Sage Therapeutics Announces Discontinuation of the Collaboration With Biogen on the Sage-324 Program
Sage Therapeutics Announces Discontinuation of the Collaboration With Biogen on the SAGE-324 Program
Roche, Biogen Kidney Disease Drug Hits Main Goal in Late-stage Study
Baird Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Biogen Stock Touches 52-week Low at $189.44 Amid Challenges
Sector Update: Health Care Stocks Softer Wednesday Afternoon
Sector Update: Health Care
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
Biogen Sued by City of Baltimore Over Alleged Tecfidera Drug Pricing 'Scheme'
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $225 to $300
Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market
Needham Reiterates Buy on Biogen, Maintains $285 Price Target
Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi
Express News | Biogen Shares up 2% Premarket After Co's Lupus Drug With Ucb Meets Main Goal of Late-Stage Trial
Eli Lilly's Alzheimer's Therapy Approved in Japan